Venturi Wealth Management LLC Buys 2,751 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Venturi Wealth Management LLC increased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 170.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 4,367 shares of the medical research company’s stock after buying an additional 2,751 shares during the period. Venturi Wealth Management LLC’s holdings in Charles River Laboratories International were worth $806,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CRL. Versant Capital Management Inc lifted its position in Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. lifted its stake in shares of Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after buying an additional 65 shares during the period. Assetmark Inc. lifted its stake in shares of Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after buying an additional 173 shares during the period. ORG Wealth Partners LLC acquired a new stake in shares of Charles River Laboratories International during the fourth quarter worth $56,000. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of Charles River Laboratories International during the third quarter worth $59,000. 98.91% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on CRL. UBS Group restated a “neutral” rating and set a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Evercore ISI boosted their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. TD Cowen boosted their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research report on Monday, November 11th. Bank of America decreased their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Finally, CLSA downgraded shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price for the company. in a research report on Monday, November 18th. Three investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $197.64.

Charles River Laboratories International Stock Up 1.7 %

CRL stock opened at $154.63 on Wednesday. The stock has a market capitalization of $7.91 billion, a P/E ratio of 19.35, a P/E/G ratio of 6.47 and a beta of 1.37. The firm has a 50-day simple moving average of $174.59 and a 200-day simple moving average of $189.16. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a 52 week low of $150.79 and a 52 week high of $275.00.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).